Aptevo files prospectus supplement to sell up to $3.17M in common stock via ATM

Aptevo Therapeutics Inc.

ATM offering of up to $3,167,548 in common stock under sales agreement with Roth Capital Partners.
As of April 29, 2025, 305,845 shares sold at $0.5946/share for $181,848 gross proceeds.
Supplement amends prior April 28, 2025 prospectus supplement; legal opinion filed as Exhibit 5.1.
Shares offered under existing S-3 registration statement (File No. 333-284969).
Paul Hastings LLP provided the legal opinion included in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.